Cytokinetics (CYTK) Stock Forecast & Price Target

$54.97

+0.44 (+0.81%)

(As of 10/18/2024 ET)

Cytokinetics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
4

Buy
11

Based on 15 Wall Street analysts who have issued ratings for Cytokinetics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, and 11 have given a buy rating for CYTK.

Consensus Price Target

$83.93
52.68% Upside

According to the 15 analysts' twelve-month price targets for Cytokinetics, the average price target is $83.93. The highest price target for CYTK is $120.00, while the lowest price target for CYTK is $60.00. The average price target represents a forecasted upside of 52.68% from the current price of $54.97.

Get the Latest News and Ratings for CYTK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cytokinetics and its competitors.

CYTK Analyst Ratings Over Time

Type	Current Forecast 10/20/23 to 10/19/24	1 Month Ago 9/20/23 to 9/19/24	3 Months Ago 7/22/23 to 7/21/24	1 Year Ago 10/20/22 to 10/20/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	15 Buy rating(s)	13 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$83.93	$80.67	$77.06	$59.29
Forecasted Upside	52.68% Upside	45.08% Upside	36.60% Upside	79.06% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

CYTK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CYTK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cytokinetics Stock vs. The Competition

Type	Cytokinetics	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	52.68% Upside	13,587.61% Upside	6.16% Upside
News Sentiment Rating	Positive News See Recent CYTK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/18/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
10/17/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00	+30.25%
10/17/2024	HC Wainwright 2 of 5 stars	Joseph Pantginis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00	+117.08%
9/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$65.00 ➝ $71.00	+27.26%
9/4/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$78.00 ➝ $78.00	+44.10%
8/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Choi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$85.00 ➝ $60.00	+6.80%
Get the Latest News and Ratings for CYTK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.
6/4/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$122.00 ➝ $92.00	+89.81%
5/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$86.00 ➝ $70.00	+45.20%
5/23/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$70.00 ➝ $60.00	+20.53%
5/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$100.00 ➝ $95.00	+92.19%
5/23/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$92.00 ➝ $70.00	+42.80%
5/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$107.00 ➝ $106.00	+65.08%
3/6/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $99.00	+49.03%
1/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$61.00 ➝ $92.00	+8.49%
1/5/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Equal Weight	$60.00 ➝ $90.00	+1.99%
8/15/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/15/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%
8/15/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+80.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:40 PM ET.

CYTK Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Cytokinetics is $83.93, with a high forecast of $120.00 and a low forecast of $60.00.
: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares.
: According to analysts, Cytokinetics's stock has a predicted upside of 52.68% based on their 12-month stock forecasts.
: Over the previous 90 days, Cytokinetics's stock had 1 downgrade by analysts.
: Cytokinetics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, and The Goldman Sachs Group in the past 90 days.
: Analysts like Cytokinetics less than other "medical" companies. The consensus rating score for Cytokinetics is 2.73 while the average consensus rating score for "medical" companies is 2.79. Learn more on how CYTK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

This page (NASDAQ:CYTK) was last updated on 10/19/2024 by MarketBeat.com Staff

From Our Partners